ÂÜÀòÂÒÂ×

Dr. Dino Miano brings more than 25 years of experience in pharmaceutical development in the areas of analytical and product development and manufacturing. Prior to joining Avalo Therapeutics, Dr. Miano served as an Executive Director at Alexion Pharmaceuticals where he spent most of his career leading the analytical and pharmaceutical development groups. Under his leadership, his teams provided analytical, formulation, and stability support to all areas of the organization including process development, devices, manufacturing, and quality control. Dr. Miano was a key partner of Global Operations in delivering clinical material from early-stage programs through commercialization. During his tenure at Alexion, Dr. Miano was an integral part of the clinical development and global commercialization of Soliris®, Strensiq®, Kanuma®, and Ultomiris® therapies for rare disease indications. He was appointed the cross-functional leader for Ultomiris® responsible for delivering drug products throughout the clinical phases of development. His work also included supporting over 20 clinical novel biologics programs for analytical and formulation development. Dr. Miano completed his postdoctoral training at the RW Johnson Research Institute. Dr. Miano holds a BSc in Chemistry/Biology from the University of Hartford, and a Ph.D. in Chemistry/Biochemistry from the University of Massachusetts.